Visus Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Visus Therapeutics was a Seattle clinical-stage biopharmaceutical company founded in 2019 by CEO Ben Bergo, developing presbyopia-correcting eye drops. Its lead asset, BRIMOCHOL PF, is a once-daily eye drop designed to correct age-related loss of near vision with up to eight hours of effect, tested in two Phase 3 pivotal trials (BRIO-I and BRIO-II). The company raised $56 million total, including a $36 million Series A in March 2021 (Johnson & Johnson Innovation–JJDC, RTW Investments) and a $20 million round in August 2021, and employed about 45–59 people.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Visus Therapeutics was founded in Seattle in 2019 to develop presbyopia-correcting eye drops, led by co-founder and CEO Ben Bergo.
- Funding
The company raised a $36 million Series A in March 2021 and a $20 million financing in August 2021, bringing total funding to $56 million.
- Merger
In December 2024, Visus merged with Tenpoint Therapeutics; the combined company operates under the Tenpoint Therapeutics name, aiming to file an NDA for the presbyopia eye drop. A crossover financing round was triggered by the deal.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.